A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario-Reference-Cited by-同舟云学术

A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario

Published:2021-04 Issue: Volume:Volume 8 Page:241-251
ISSN:2253-5969
Container-title:Journal of Hepatocellular Carcinoma
language:en
Short-container-title:JHC

Author:

Dipasquale Angelo^ORCID,Marinello Arianna,Santoro Armando

Publisher

Informa UK Limited

Subject

General Medicine

Reference59 articles.

1. Globocan. The IARC Global Cancer Observatory. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp. Accessed March 9, 2021.

2. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030

3. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

4. Transection of the oesophagus for bleeding oesophageal varices

5. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breaking Down the Arsenal: Recent Progress in the Nanotherapeutic Strategies for Hepatocellular Carcinoma Treatment;Advanced Therapeutics;2024-07-06

2. Critique on “Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights” [Letter];Pragmatic and Observational Research;2024-07

3. Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis;Journal of Liver Cancer;2024-03-31

4. Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer;Journal of Molecular Liquids;2024-03

5. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2024-03